Brief: Haemonetics Reaffirms Fiscal 2026 Guidance
07/08/2025 13:19
Aug 7 (Reuters) - Haemonetics Corp HAE.N: : REAFFIRMS FISCAL 2026 GUIDANCE QTRLY REVENUE $321 MILLION, ADJUSTED EPS $1.10 Q1 EARNINGS PER SHARE VIEW $1.02, REVENUE VIEW $304.4 MILLION -- LSEG IBES DATA FY2026 EARNINGS PER SHARE VIEW $4.87, REVENUE VIEW $1.31 BILLION -- LSEG IBES DATA Source text: ID:nPn8s1VVNa Further company coverage: HAE.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Haemonetics
See all newsBrief: Haemonetics Announces FDA Approval Of Perqseal® Elite Vascular Closure System
Haemonetics says FDA clears vascular closure device
US STOCKS ON THE MOVE-Palantir, Haemonetics
U.S. STOCKS ON THE MOVE-Palantir, Haemonetics, Starbucks
Haemonetics surges as CSL plans to move all US plasma centers to its devices